Nahdi Medical Company
4164.SRSAUHealthcare● Active
$95.40
$-0.10(-0.10%)
Market Cap$12.4B
P/E Ratio—
52W High$132.1
52W Low$91
Nahdi Medical Company (4164.SR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
4164.SR · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.81
Revenue
$2.79B
Est. $2.71B · +3.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
4164.SR reports quarterly as a SAU-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 6, 2026 | — | $1.81 | — | $2.79B | $2.71B | +3.1% |
| — Q1 FY2026 | Mar 9, 2026 | $1.19 | $1.19 | +0.0% | $2.59B | $2.51B | +3.2% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $1.79 | $1.83 | +2.2% | $2.53B | $2.65B | -4.5% |
| ▲ Q2 FY2025 | May 7, 2025 | $1.49 | $1.96 | +31.5% | $2.63B | $2.47B | +6.8% |
| — Q1 FY2025 | Mar 10, 2025 | $1.21 | $1.21 | +0.0% | $2.36B | $2.39B | -1.2% |
| ▼ Q4 FY2024 | Oct 30, 2024 | $1.54 | $1.40 | -9.1% | $2.35B | $2.27B | +3.5% |
| ▲ Q3 FY2024 | Jul 31, 2024 | $1.54 | $1.91 | +24.0% | $2.47B | $2.31B | +6.9% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
$1.81
EPS Est.
—
EPS Surpr.
—
Revenue
$2.79B
Q1 FY2026
Mar 9, 2026
EPS Actual
$1.19
EPS Est.
$1.19
EPS Surpr.
+0.0%
Revenue
$2.59B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$1.83
EPS Est.
$1.79
EPS Surpr.
+2.2%
Revenue
$2.53B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$1.96
EPS Est.
$1.49
EPS Surpr.
+31.5%
Revenue
$2.63B
Q1 FY2025
Mar 10, 2025
EPS Actual
$1.21
EPS Est.
$1.21
EPS Surpr.
+0.0%
Revenue
$2.36B
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
$1.40
EPS Est.
$1.54
EPS Surpr.
-9.1%
Revenue
$2.35B
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
$1.91
EPS Est.
$1.54
EPS Surpr.
+24.0%
Revenue
$2.47B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $1.19 | $1.19 | $1.19 | 1 |
| Q3 FY2025 | $1.64 | $1.64 | $1.64 | 1 |
| Q2 FY2025 | $1.79 | $1.79 | $1.79 | 1 |
| Q1 FY2025 | $1.49 | $1.49 | $1.49 | 1 |
| Q4 FY2024 | $1.21 | $1.21 | $1.21 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $2.7B | $2.7B | $2.8B | 2 |
| Q4 FY2025 | $2.5B | $2.5B | $2.5B | 2 |
| Q3 FY2025 | $2.5B | $2.5B | $2.5B | 2 |
| Q2 FY2025 | $2.5B | $2.6B | $2.6B | 3 |
| Q1 FY2025 | $2.5B | $2.5B | $2.5B | 1 |
| Q4 FY2024 | $2.4B | $2.4B | $2.4B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 6, 2026 | — | $103.00 | $101.70 | -1.26% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +0.0% | $102.20 | $103.20 | +0.98% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +2.2% | $130.30 | $123.10 | -5.53% |
| ▲ Q2 FY2025 | May 7, 2025 | +31.5% | $113.00 | $121.20 | +7.26% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +0.0% | $118.00 | $115.80 | -1.86% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -9.1% | $129.40 | $124.40 | -3.86% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +24.0% | $131.00 | $132.80 | +1.37% |
| — Q2 FY2024 | May 8, 2024 | — | $137.00 | $133.60 | -2.48% |
Q2 FY2026-1.26%
Report Date
May 6, 2026
EPS Beat/Miss
—
Price Before
$103.00
Price After
$101.70
Q1 FY2026+0.98%
Report Date
Mar 9, 2026
EPS Beat/Miss
+0.0%
Price Before
$102.20
Price After
$103.20
Q3 FY2025-5.53%
Report Date
Jul 30, 2025
EPS Beat/Miss
+2.2%
Price Before
$130.30
Price After
$123.10
Q2 FY2025+7.26%
Report Date
May 7, 2025
EPS Beat/Miss
+31.5%
Price Before
$113.00
Price After
$121.20
Q1 FY2025-1.86%
Report Date
Mar 10, 2025
EPS Beat/Miss
+0.0%
Price Before
$118.00
Price After
$115.80
Q4 FY2024-3.86%
Report Date
Oct 30, 2024
EPS Beat/Miss
-9.1%
Price Before
$129.40
Price After
$124.40
Q3 FY2024+1.37%
Report Date
Jul 31, 2024
EPS Beat/Miss
+24.0%
Price Before
$131.00
Price After
$132.80
Q2 FY2024-2.48%
Report Date
May 8, 2024
EPS Beat/Miss
—
Price Before
$137.00
Price After
$133.60
Avg Beat Reaction+0.44%
Avg Miss Reaction-3.86%
Beat Rate5 / 8 quarters
Largest Move+7.26% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: 4164.SR ends December
Nahdi Medical Company (4164.SR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.81 (in line with the analyst consensus of —). 4164.SR has beaten EPS estimates for 4 consecutive quarters. The next 4164.SR earnings date is expected around September 2, 2026.
Each quarter, investors track 4164.SR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. 4164.SR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
4164.SR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
4164.SR earnings · 4 questionsNahdi Medical Company's next earnings report is expected around September 2, 2026. 4164.SR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; 4164.SR historically reports after market close (AMC).
4164.SR earnings datewhen is 4164.SR earnings4164.SR next earnings datewhen does 4164.SR report earnings4164.SR earnings calendar
▸ Source: FMP · Nahdi Medical Company SEC filings · US GAAP · Nahdi Medical Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026